WO2007065314A1 - Composition pour le traitement d'une hepatopathie virale - Google Patents

Composition pour le traitement d'une hepatopathie virale Download PDF

Info

Publication number
WO2007065314A1
WO2007065314A1 PCT/CN2006/000007 CN2006000007W WO2007065314A1 WO 2007065314 A1 WO2007065314 A1 WO 2007065314A1 CN 2006000007 W CN2006000007 W CN 2006000007W WO 2007065314 A1 WO2007065314 A1 WO 2007065314A1
Authority
WO
WIPO (PCT)
Prior art keywords
content
vitamin
liver
compound preparation
hepatitis
Prior art date
Application number
PCT/CN2006/000007
Other languages
English (en)
Chinese (zh)
Inventor
Hongping Yie
Zuolin Zhu
Meng M. Sun
Qingsheng Zhang
Zuolian Zhu
Original Assignee
Pficker Pharmaceuticals, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pficker Pharmaceuticals, Ltd. filed Critical Pficker Pharmaceuticals, Ltd.
Publication of WO2007065314A1 publication Critical patent/WO2007065314A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • This book relates to the field of biotechnology and wood, and involves a prescription for the treatment of viral liver disease.
  • Viral liver disease is one of the potentially fatal chronic diseases. In the middle 0, there are liver virus carriers. Those who currently have chronic symptoms of liver virus. 2 Chronic liver patients 3000. Hepatitis 50 and 60 have hepatitis, and about three-thirds of people with hepatitis have liver cirrhosis and liver cancer. The epidemic of the population in China resulted in the infection of the hepatitis virus 3.0 or 4,000 infected patients with 7,000 viral hepatitis. The specific effect of safe and effective viral hepatitis is important.
  • Patients with chronic liver disease generally have hypocalcemia and hypocalcemia can also cause the same "cramp" performance.
  • the high function of patients with chronic liver disease causes increased excretion in metabolism (2 decreases in patients with liver disease (3) increased excretion caused by taking certain drugs such as diuresis. Therefore, patients with liver disease should pay attention to enhanced absorption.
  • Hepatitis virus HCV is 100 times faster than RA virus and it is still alive. Therefore, hepatitis virus vaccines are compared.
  • Liver disease The letter is actually N, but the liver virus has a third part (s ge s a ded). Because of the existence, the speed of the liver virus and the vaccine is likely to be less than the speed of the liver virus.
  • the cause of viral liver cirrhosis is the constant cell.
  • the normal collapse function of the cell is to regenerate some parts that fill the "collapse". It is a normal function of Hue. But if the cell is constantly regenerating inside
  • the effective immunity of the liver virus Due to the rapidity of the liver virus and the establishment of the immune system within the rest, the effective immunity of the liver virus is rebuilt and the suppression of the virus improves the inflammation of the veins, reduces the normal function, and enhances the regeneration of normal functions. .
  • the most reasonable method of viral hepatitis is the comprehensive protection of the patient, including the completeness of the functional cells of the hepatitis virus and the rabbits, the regeneration of the stimulating cells, the normal function of the progenitor cells of the stimulating cells, and the decline of the stimulating factors.
  • the wood to be solved in this project is to study new anti-viral liver diseases with high safety and asexuality.
  • the prescription system has the functions of infection and enhanced regeneration. This book provides a prescription for the treatment of viral liver disease.
  • Active ingredients for suppressing virus regeneration include licorice gycy hz
  • (S y arn) L-Ca e has vascular endothelial cell growth factor VEGF extract As aga sEx ac biotin glucose os e etc. as well as necessary and absorbed biotin.
  • Glycyrrhiza glycyrrhiza is a glycyrrhizic acid (gycy hzcacd). Glycyrrhizin has a better role in inhibiting the proliferation of viruses.
  • Licorice is a compound that has been studied a lot. As early as 1921 a e hao, the compound licorice was obtained ev. H. Aca4 00 1921 which was determined at 950 J. Che. Soc 1983 1950 956 modified determination BoChem. J. 63 9 1956. The glycyrrhizin's physical function involves many aspects, mainly including antiviral, immune function, antibacterial, steroids, hormones, etc. It can prevent and treat cirrhosis. Licorice is an antiviral
  • Licorice is a direct nuclear virus that blocks the antiviral effect by inhibiting the proliferation of the virus. Licorice inhibits the proliferation of HIV. 0.5 g licorice inhibits the proliferation of AIDS virus by more than 98%. 0.125 gm inhibits 50% formation. This suggests that glycyrrhizin does not inhibit the anti-specific activity of AIDS virus but is a function of T lymphocytes.
  • Glycyrrhizin can inhibit the growth of banded virus outside the rest (D 0.7mmo /) and can directly virus. Glycyrrhizin does not inhibit hormones and may also cause local solid (solid It is a hormone secreted by the adrenal glands that promotes absorption and secretion. Solid deficiency causes low blood and high blood. Low blood stimulates uric acidification and high blood pressure weakens uric acidification. Has a strengthening effect. Glycyrrhiza chronic hepatitis is also effective A va Res. 1996 ay 3023 71-7 and J epao. 1994 Oc 214 6019. It enhances the role of NK cells.
  • the immune effect of glycyrrhizin shows that the phagocytic activity that is not specifically enhanced can clear the inhibitory inhibitory activity.
  • Licorice inhibits the production of prostaglandin PE in the large abdominal cavity and inhibits the release of arachidic acid.
  • the inhibition of licorice PE is due to the inhibition of the activity of P synthesis.
  • the peritoneal cavity of mice treated with licorice can be increased.
  • Glycyrrhiza the cells are established from mouse skeletal leukemia cells and are derived from 1 L and Y FN Y has the same L that can increase multi-LP stimulation.
  • intravenous injection of 2 ug kg of licorice 2 cells enhanced the F-producing ability.
  • Mice were intraperitoneally injected with 330 g kg of licorice for 20 h and the peak of FN activity. Hugh shows the licorice itself
  • Glycyrrhizin enhances the growth of FN. Some people inhibit it by inhibiting the activity of P synthesis.
  • the effect is better than the use of e ymp o a.200 4 J-2 191 and epao Res.200 2 1-8 and different from the use of other synthetic use of licorice without any side effects
  • C Thex 989 19 is present in all normal cells
  • the presence of prototype ⁇ S is the main non-protein-based compound in the cell.
  • the direct or indirect effects include genes, activity and generation, cell preservation, amino acid characteristics, immune function, etc. Oxidation or compounds can reduce the content of GS in the cell or make it specifically oxidize GSSG, and can also use the special GS of AP.
  • Caprylic acid is a natural oxidant that exists in the body of the body. It can make both water-soluble biotin and soluble biotin improve both inside and outside the cell, and the oxidation characteristics of caprylic acid can regenerate biotin and biotin E. Caprylic acid can "stand in” for other oxidation shortages. In other words, if you are absent, you will take over their work if you lack vitamin E or C. Caprylic Acid Oxidation Effect Biotin A, C, E eliminates free radicals that accelerate aging and cause disease. It is probably the most effective one among the natural oxidation known at present. Caprylic acid, Pos ea h ews 998 o17 1921
  • Caprylic acid can synthesize well endotoxin hepatitis symptom function.
  • the oxidative system of patients with AIDS V and viral hepatitis is usually weak. Due to the lack of oxidation, the oxidation stimulates the virus to prevent the virus from multiplying.
  • Caprylic acid can stimulate the biotin C, Pos. Ea h ews. 998 o 17) 145 in the blood of patients. Increased sulfide improves the ratio of T4 / T8 lymphocytes and reduces free radicals. J. App. Toxco 2004, 4 216. .
  • D D is an amino acid necessary for Hugh, which has a strong detoxification effect and inhibits virus regeneration.
  • the konixi juice is very good for reducing the symptoms of colds and palliative diseases in patients (to Sce ce ews 999 September and 999 March etc.
  • konixi juice can effectively inhibit the division control of the virus Viral derivation Pa a ed. 1 78 33 89102).
  • Cornicia can stimulate fibrate
  • Biotin E Biotin E The reproductive and breeding image of the lack of reproductive damage of the whole thing and it can bear children. Biotin E can promote the absorption, utilization and utilization of biotin A. The characteristics of biotin E and its distribution in humans have a series of functions such as free radical aging and cell regeneration, enhancing rabbit epidemic power, and cardiovascular protection. Free radicals exist in the normal physiology of various chemical reactions. Normal physiology has an important function. If free radicals cause free radicals, the oxidation of cell membranes and fatty acids will not be oxidized. A large amount of new oxides are formed in the cell membranes and the cells are larger than protein nucleic acids. Free radicals react with biotin E to capture free radicals.
  • biotin E radical oxidation is very high. In the study of the lack of biotin E or the immune function of the organism, it is not the rest of the immune system and the cellular immunity is also very large. Research in the 1980s clarified that biotin E is one of the important factors of cell growth. One of the most recent studies of cell death is the depletion of biotin E in cells FeeRadcRes. 996256 4616. Biotin E is more effective in acute liver Ca ce Res. 2003 63 670715 has good A v a Res. 200 492 75-81 and e ed. 998 J282 1567 and enhances the patient's immunity kSpava. 992 4 901 and.
  • liver patients have very high levels of biotin E in their blood.
  • Cellular growth Ca ce Res. 982 3858-63 Three years including 20847 people with moderate prevention Bo Tace Ee Res. 989 20 -2 1 22 prevention of prevention
  • Biotin C is an essential biotin for humans and generally plays an important role in the oxidative effect of cellular respiration. Biotin C is required for the formation of cells and proproteins, the synthesis of sterols, the specialization of acids and yos e). Biotin C is necessary for the repair of healthy gums. It has the functions of promoting blood circulation, eliminating, improving autologous blood cells, enhancing immunity, preventing blood diseases, fractures and other multi-spirit functions, reducing sterols and high blood, preventing vein sclerosis and poisoning. effect. Biotin C and The detoxification effect of lead poisoning in water sharing is higher than that using water
  • Zuo Zuo is a synthetic compound Yu. the study Combine left or right with chronic hepatitis patients. Zuo enhances the immunity of Hugh but cannot be used otherwise it can cause bone marrow suppression.
  • Water Water is the main active ingredient of M kThste Chinese extracted from Xiao Shen Yu. It has been in Europe for more than a thousand years, and its functions are very popular. 949 plays a role in patients affected by carbon chloride and has the function of hepatitis. Early this year scientists
  • LL is also a necessary supplement in fat to promote oxidative decomposition of fatty acids.
  • Their left in the blood with liver disease is lower than that of healthy people [eVaPeda 989 5 24751. It is mainly used and the left organ of the whole body is sick and the left is used to increase the discharge of liver disease patients who cause systemic cirrhosis. 997 25 148-53 So the liver patient left is very important Sc. 99659 ⁇ 157999 A hamacohe .2000 345 630-8.
  • the left side increases the rabbit's epidemic power Tea e pdae. 998 0 46
  • the latest research results The preventive effect of left liver disease is to suppress the abnormal function of zaoxiu and is very good JCa ce 2005 J 33 719-29.
  • the formula used in this specification includes all of the above active ingredients.
  • the formula may contain a mixture of each active ingredient and may also be used together.
  • the establishment of the active ingredients in this specification is based on the fact that they do not have any cross-effects. All the active ingredients used in this specification are not subject to any cross-effects.
  • the content of glycyrrhizic acid is 500 mg, 1500 mg, and the most suitable is 1000 mg.
  • Conixi or extracts can be specially formulated to 50 mg of biotin E with a force of 50 3000 units of commonly used force of 100 solid units of 200 solid parking spaces the most suitable amount of force of 0 solid units to 600 sheep
  • the content of left force is 50 mg
  • the content of hydrogen is mg 800 mg, commonly used, 50 mg, 600 mg, and 200 mg, 500 mg.
  • the acid content is 50 micrometers and 2000 micrometers.
  • the strength of the L machine is 100 mg 1000 mg, the usual dosage is 50 mg, 800 mg, and the most effective is 200 mg, 500 mg.
  • the content of the extract is 500mg 3000mg.
  • the extract used in this article is more than 70% yellow powder.
  • the content of vitamins is 10 mg, 2000 mg, and the usual dosage is 50 mg, 800 mg, and the most suitable is 100 mg, 700 mg.
  • the content of glucose is 50 mg 200 mg
  • the content of force 200 mg 500 mg The content of caprylic acid. 0 mg 3000 mg commonly used force 5.0 mg 1200 mg the most suitable force 40 mg 700 mg or the effective caprylic acid dosage to 2.0 mg to 200 mg kg Hugh preferably to 8.0 mg kg to 70 mg kg Hugh
  • the content of 10 is 1.0 mg to 1000 mg. Commonly used is 5.0 mg. 800 mg. The most suitable is 40 mg. To 600 mg.
  • Lactose force filling and blending Acaca) Arabian force emulsifying and blending Sea c acd) Force emulsifying and blending ydoxypopy mehyce ose) Basing force blending and blending sucrose strength Poye ye e gyco Force filling, emulsifying, and od ed odSach
  • the food is used as a force-filling agent, as well as Soybea O1 soybean oil and ec h as a force-soluble substance and a doxde dioxide is used as a wait-and-see.
  • the square system in this Ming Dynasty can be the rest system.
  • the rest system can be a solution or an aqueous solution or and etc.
  • all active ingredients will be possible to use them.
  • all the effective ingredients can be in the same medium molding, or different effective ingredients in each own molding.
  • the dosage of this prescription system etc.
  • the daily consumption of oral diseases depends on many factors including the age, age, sex, inevitable symptoms, diseases, and so on.
  • the various methods of this system make the solid rest system in the original knowledge can be the existing trees of the gods. If all the effective ingredients are in the same medium molding, the matching effective ingredients and or the shape or the shape are generally mixed into a mixture, and then the other effective ingredients and the shape are added and mixed evenly. Mixing can be mixing aag, Mix s gg g, blend and mix be d, etc. Mixture or made or.
  • Plant stress or soluble substances such as,,, palm, soybean oil,, Ca oa, grape, etc. are commonly used
  • the medicine of this book is the existing wood of each god. Generally, the matching effective ingredients, or soluble materials, and or more excipients are mixed into a mixture, and then other effective ingredients and excipients are added to mix the mixture.
  • the prescription system in this Ming Dynasty does not have better anti-viral ability and the anti-virus used is stronger than the prescription system in this Ming Dynasty to enhance the immunity of the patients and prevent chronic chronic diseases.
  • the recipe in this invention has the functions of preventing infection and enhancing cell regeneration.
  • Group 3 is the evolution of N in the front.
  • the left in 3 indicates the number of the previous phase 100% and the right indicates the number of the phase N. Hugh way
  • the recipe in this specification can be a combination of all the active ingredients.
  • the recipe listed below is a better description of the text, not the recipe in this specification, which includes the following combination of active ingredients.
  • the following table shows the recipes.
  • the product formula can be used for either.
  • the general method of life of the Guxiu type is as follows
  • step 5 If necessary, it will be overlaid on the one obtained in step 4. Then the uniformity obtained in step 1 is directly shaped.
  • the functional human cell cells in the present prescription for preventing infection are infected with hepatitis virus (HB) of 50 times the genetic amount under the prescription and prescription for 14 hours. It is doco tso e with 35X 6 hydrocodine added hems cc ae) 2% D SO 5% adult serum and 5% bovine serum (ea Ca Se) (ed cut. After the infection is completed, wash away all the methods to change the amount of E SA infected cells on the twelfth day The secretion of BsAg. Each formula has a prescription and a BsAg-based strength
  • the cost is almost average.
  • the dosage of the formula is secreted by the octanoic acid in the formula (medium octanoic acid is the surface antigen bAg obtained from the 8-square system of infected cells.
  • liver viremia e.
  • liver virus in the Azai prescription formula is not affected by other ingredients and the Aahe formula recipe 1 removes the liver virus within a week (there is also a large amount of liver virus out 32 34).
  • Formulas with artificial liver virus suppression such as formula 9 also have the ability to suppress and clean up liver viruses (2). 4 Renewal of heightened cells (epaoc eu ove
  • the system of increasing the height of the cell is updated, that is, the new system has the ability to improve regeneration, and the synthesis is smaller than Ru, etc., but it does not have the function of improving cell regeneration and they have no neurological function.
  • J. V o. 994 68 5469-5475 There is no mature virus core protein bright vra ceocapsds in cell division rapidly. Using the same inhibitory virus to regenerate the two, the main effective components of the inhibitory virus to regenerate are the same. Only when the cell regeneration is accelerated will the rate of removal of internal N be accelerated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composition pour traitement d'hépatopathie renfermant les principes actifs suivants : médicaments inhibant la duplication et la régénération du virus, médicaments accentuant l'immunocompétence des humains, médicaments protégeant et régénérant le foie et médicaments protégeant les reins. Cette composition a un pouvoir curatif élevé, une innocuité et un résistance aux virus élevée, ne produit pas d'effets croisés et renforce l'immunocompétence du patient, De plus, cette composition peut empêcher l'infection par l'hépatite B et favorise la régénération des cellules du foie.
PCT/CN2006/000007 2005-12-08 2006-01-05 Composition pour le traitement d'une hepatopathie virale WO2007065314A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200510130914.0 2005-12-08
CN2005101309140A CN1895671B (zh) 2005-12-08 2005-12-08 治疗病毒型肝病的复方制剂

Publications (1)

Publication Number Publication Date
WO2007065314A1 true WO2007065314A1 (fr) 2007-06-14

Family

ID=37608413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2006/000007 WO2007065314A1 (fr) 2005-12-08 2006-01-05 Composition pour le traitement d'une hepatopathie virale

Country Status (2)

Country Link
CN (1) CN1895671B (fr)
WO (1) WO2007065314A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364098B1 (fr) * 2008-12-16 2016-10-12 Hill's Pet Nutrition, Inc. Composition alimentaire contenant un anti-oxydant contribuant à améliorer l'immunité antivirale des animaux de compagnie
CN101961312B (zh) * 2010-09-28 2012-10-03 北京世纪博康医药科技有限公司 一种注射用硫辛酸组合物
CN104431368A (zh) * 2014-12-15 2015-03-25 中国水产科学研究院长江水产研究所 一种促进鱼类健康生长的复合饲料添加剂及制备方法
CN104998250B (zh) * 2015-07-29 2018-05-29 福建广生堂药业股份有限公司 一种恩替卡韦与甘露聚糖肽药物组合物及其制备方法
CN105535930A (zh) * 2015-12-21 2016-05-04 天津中津药业股份有限公司 一种药物保健组合物
CN105727259A (zh) * 2016-02-04 2016-07-06 单秀娟 一种用于治疗肝源性肾损害的复方护理剂及其制备方法
CN106511447A (zh) * 2016-10-28 2017-03-22 肖远 一种细胞障碍修复营养补充方法及其药物配方
CN115120561B (zh) * 2022-06-30 2023-12-19 中国药科大学 组合药物金属有机杂化纳米组装体及其应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1129113A (zh) * 1995-01-20 1996-08-21 赵汝熹 爱滋病特效治疗剂
CN1181975A (zh) * 1997-10-07 1998-05-20 孟平安 静脉曲张注射液
CN1223887A (zh) * 1998-01-22 1999-07-28 王维谦 溶癌素
WO2001064211A1 (fr) * 2000-03-03 2001-09-07 Lee Shu Wen Médicament spécifique pour le traitement du sida
CN1338932A (zh) * 1999-02-16 2002-03-06 人机能改善中心国际有限公司 硫辛酸与抗坏血酸组合在治疗癌症中的应用
CN1413727A (zh) * 2002-09-09 2003-04-30 凌一峰 一种根治艾滋病的药物组合物
CN1477958A (zh) * 2000-10-31 2004-02-25 高露洁-棕榄公司 组合物及方法
CN1520845A (zh) * 2003-02-12 2004-08-18 宇 董 一种鼻腔给药治疗感冒的药物
CN1559605A (zh) * 2004-02-17 2005-01-05 芳 方 复方芦荟保健片
CN1611260A (zh) * 2003-11-01 2005-05-04 杨喜鸿 阿德福韦酯的组合用药物
CN1686547A (zh) * 2005-03-30 2005-10-26 淮北市辉克药业有限公司 长期使用的治疗糖尿病的复方制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7341717B2 (en) * 2001-04-13 2008-03-11 Gpc Biotech Ag Therapeutic targets for treatment of HCV infections, methods of treating HCV infections and compounds useful therefor
CN1236772C (zh) * 2002-12-23 2006-01-18 刘宝顺 治疗乙型肝炎的药物组合物
CN1314444C (zh) * 2003-03-20 2007-05-09 蔡海德 一种治疗糠尿病及其并发症和病毒性肝炎的组合药物及其制备方法
CN1513473A (zh) * 2003-08-13 2004-07-21 杨喜鸿 包含阿德福韦和硒化合物的联合用药物

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1129113A (zh) * 1995-01-20 1996-08-21 赵汝熹 爱滋病特效治疗剂
CN1181975A (zh) * 1997-10-07 1998-05-20 孟平安 静脉曲张注射液
CN1223887A (zh) * 1998-01-22 1999-07-28 王维谦 溶癌素
CN1338932A (zh) * 1999-02-16 2002-03-06 人机能改善中心国际有限公司 硫辛酸与抗坏血酸组合在治疗癌症中的应用
WO2001064211A1 (fr) * 2000-03-03 2001-09-07 Lee Shu Wen Médicament spécifique pour le traitement du sida
CN1477958A (zh) * 2000-10-31 2004-02-25 高露洁-棕榄公司 组合物及方法
CN1413727A (zh) * 2002-09-09 2003-04-30 凌一峰 一种根治艾滋病的药物组合物
CN1520845A (zh) * 2003-02-12 2004-08-18 宇 董 一种鼻腔给药治疗感冒的药物
CN1611260A (zh) * 2003-11-01 2005-05-04 杨喜鸿 阿德福韦酯的组合用药物
CN1559605A (zh) * 2004-02-17 2005-01-05 芳 方 复方芦荟保健片
CN1686547A (zh) * 2005-03-30 2005-10-26 淮北市辉克药业有限公司 长期使用的治疗糖尿病的复方制剂

Also Published As

Publication number Publication date
CN1895671B (zh) 2012-11-28
CN1895671A (zh) 2007-01-17

Similar Documents

Publication Publication Date Title
WO2007065314A1 (fr) Composition pour le traitement d'une hepatopathie virale
JP6550370B2 (ja) 脂質レベルを低下させるロイシンおよびニコチン酸
TW201402130A (zh) 包含蘿蔔硫素之組成物或包含一種蘿蔔硫素前驅物及鎂之組成物
CN102264222B (zh) 抗病毒补剂
WO2020253835A1 (fr) Composition contenant des nitrates et des vitamines, son procédé de préparation, formulation associée et utilisation associée
CN111991401A (zh) 一种化合物在治疗SARS-CoV-2感染中的应用
JP2014533729A (ja) ケルセチンを含有するｃ型肝炎ウイルスの感染を治療するための医薬品
AU2021257523B2 (en) Ginsenoside composition having alcoholic fatty liver-preventing and -treating function
TWI269656B (en) Therapeutical composition for hepatitis C
TWI359667B (en) Formulation for oral administration having a healt
Wang et al. Protective effects of corni fructus extract in mice with potassium oxonate–induced hyperuricemia
JPH07330593A (ja) 疲労改善剤
WO2000043017A1 (fr) Composition de medicaments anti-vih, composes anti-cortisol, et procede de diminution des effets secondaires des medicaments anti-vih chez l'homme
CN114129572A (zh) 一种协同抑制汉防己甲素诱导的药源性肝损伤的药物组合物
CN106349318A (zh) 一种五环三萜化合物在制备治疗肥胖症药物中的应用
KR20170012169A (ko) 경구용 복합제제
Chen et al. Beneficial effects of sanguisorbae radix in renal dysfunction caused by endotoxin in vivo
EP3603628A1 (fr) Composition de réduction du poids et de réduction de la graisse corporelle et produit pharmaceutique et application correspondants
KR101086040B1 (ko) 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체
KR20170026241A (ko) 경구용 복합제제
JP4896531B2 (ja) 血中ＣｏＱ１０量を増加させる医薬組成物
TWI717757B (zh) 含有卡琪花蒂瑪萃取物之組成物在改善急性出血性貧血之用途
KR19990066786A (ko) 베르겐닌 및 그 유도체를 유효성분으로 하는 간기능 개선제
RU2319497C2 (ru) Средство для повышения устойчивости организма к вирусным и вирус индуцированным заболеваниям
JP2003226650A (ja) 医薬用組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06705433

Country of ref document: EP

Kind code of ref document: A1